{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:20:08Z","timestamp":1766989208793,"version":"3.48.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01469-0","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T08:16:45Z","timestamp":1758183405000},"page":"847-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small-Cell Lung Cancer in Italy"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3798","authenticated-orcid":false,"given":"Andrea","family":"Marcellusi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Tempre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buonfiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104108","volume":"190","author":"C Catania","year":"2023","unstructured":"Catania C, Filippi AR, Sangalli C, et al. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION group. Crit Rev Oncol Hematol. 2023;190: 104108.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1469_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer. Bethesda (MD): SEER Program. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html (Accessed 3 Jul 2025)"},{"issue":"9928","key":"1469_CR3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561\u201371.","journal-title":"Lancet"},{"issue":"5","key":"1469_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jamaoncol.2024.0043","volume":"10","author":"C Rolfo","year":"2024","unstructured":"Rolfo C, Russo A. The chemoimmunotherapy revolution in resectable NSCLC \u2013 the times they are a-changin\u2019. JAMA Oncol. 2024;10(5):569\u201370.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1469_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13696998.2023.2188844","volume":"26","author":"V Escudero-Vilaplana","year":"2023","unstructured":"Escudero-Vilaplana V, Collado-Borrell R, De Castro J, et al. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. J Med Econ. 2023;26(1):445\u201353.","journal-title":"J Med Econ"},{"issue":"10","key":"1469_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907\u201319.","journal-title":"Ann Oncol"},{"issue":"9","key":"1469_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","volume":"18","author":"JE Chaft","year":"2021","unstructured":"Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1469_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907\u201319.","journal-title":"Ann Oncol"},{"issue":"10308","key":"1469_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"key":"1469_CR10","first-page":"53","volume":"10","author":"A Marcellusi","year":"2023","unstructured":"Marcellusi A, Ragonese A, Marinozzi A, et al. Buone pratiche per lo sviluppo dei modelli di budget impact a livello regionale [Good practices for the development of budget impact models at regional level]. Glob Reg Health Technol Assess. 2023;10:53\u201361.","journal-title":"Glob Reg Health Technol Assess"},{"key":"1469_CR11","unstructured":"Agenzia Italiana del Farmaco (AIFA). LINEE GUIDA PER LA COMPILAZIONE DEL DOSSIER A SUPPORTO DELLA DOMANDA DI RIMBORSABILIT\u00c0 E PREZZO DI UN MEDICINALE ai sensi del D.M. 2 agosto 2019 [Guidelines for completing a dossier to support an application for reimbursement and price of a medicinal product, pursuant to Ministerial Decree of August 2, 2019]. https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf (Accessed Feb 2024)."},{"key":"1469_CR12","unstructured":"Associazione Italiana Registro Tumori (AIRTUM) - I numeri del Cancro 2023 - Last update February 2024."},{"issue":"10","key":"1469_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007047","volume":"11","author":"C Zhou","year":"2023","unstructured":"Zhou C, Srivastava MK, Xu H, et al. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. J Immunother Cancer. 2023;11(10): e007047.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1469_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030363","volume":"16","author":"DL Cortinovis","year":"2023","unstructured":"Cortinovis DL, Perrone V, Giacomini E, et al. Epidemiology, patients\u2019 journey and healthcare costs in early-stage non-small-cell lung carcinoma: a real-world evidence analysis in Italy. Pharmaceuticals (Basel). 2023;16(3): 363.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"9","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1097\/JTO.0000000000000618","volume":"10","author":"JJ Hung","year":"2015","unstructured":"Hung JJ, Yeh YC, Jeng WJ, et al. Prognostic factors of survival after recurrence in patients with resected lung adenocarcinoma. J Thorac Oncol. 2015;10(9):1328\u201336.","journal-title":"J Thorac Oncol"},{"key":"1469_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-030-79308-1_4","volume":"1342","author":"DL Kaen","year":"2021","unstructured":"Kaen DL, Minatta N, Russo A, et al. Immunotherapy in lung cancer: are the promises of long-term benefit finally met? Adv Exp Med Biol. 2021;1342:113\u201342.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1469_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamaoncol.2023.5276","volume":"10","author":"HJ West","year":"2024","unstructured":"West HJ, Kim JY. Rapid advances in resectable non-small cell lung cancer: a narrative review. JAMA Oncol. 2024;10(2):249\u201355.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1469_CR19","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O'Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274\u201386.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1469_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"issue":"18","key":"1469_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"21","key":"1469_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"8","key":"1469_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2217\/imt-2022-0311","volume":"15","author":"M Das","year":"2023","unstructured":"Das M, Ogale S, Jovanoski N, et al. Cost-effectiveness of adjuvant atezolizumab for patients with stage II\u2013IIIA PD-L1+ non-small-cell lung cancer. Immunotherapy. 2023;15(8):573\u201381.","journal-title":"Immunotherapy"},{"key":"1469_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894656","volume":"12","author":"P Chen","year":"2022","unstructured":"Chen P, Yang Q, Li Y, et al. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB\u2013IIIA resectable NSCLC after adjuvant chemotherapy. Front Oncol. 2022;12: 894656.","journal-title":"Front Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01469-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:18:20Z","timestamp":1766989100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01469-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01469-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"28 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM received an unrestricted grant from ROCHE Italy for the preparation and revision of this paper. MBe, MBu, and RT are employees of Roche S.p.A., a pharmaceutical company that may have an interest in the subject matter of this manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position of Roche S.p.A. The company had no role in the model design, data interpretation, or manuscript drafting beyond the affiliations of the named authors. AR has no conflicts of interest relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The datasets generated and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics approval was not required for this study as it is based solely on previously published data and does not involve any direct patient contact, intervention, or access to individual patient-level information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code is available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception. AM, MBe, and AR developed the study design. AM conducted the statistical analysis and derived the analytical results. AM and MBe wrote the first draft of the manuscript. All authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}